Ref. 2024-026-01 Lab Manager at the Tumor Immunology & Immunotherapy Group
Reference: 2024-026-01
Application deadline: until position filled.
Number of vacancies: 1
Job description:
The Vall d´Hebron Institute of Oncology´s (VHIO) Tumor Immunology and Immunotherapy Group, headed by Dr. Alena Gros, is currently recruiting a lab manager. The successful candidate will be part of the scientific team and will be directly involved in many of the group’s ongoing projects which aim to develop personalized T-cell therapies for the treatment of solid cancers.
We seek a motivated, team-oriented individual with previous experience in biomedical research laboratory within depth knowledge of laboratory management processes and procedures and highly skilled in cell/tissue processing and molecular biology, including single cell sequencing technologies. Experience with animal experimentation is preferred. The ideal candidate must be organized, efficient, and have strong interpersonal and communication abilities to manage the team effectively. This person must also have the technical expertise and problem-solving capabilities to establish novel methods in the lab.
Application:
Potential candidates should submit a curriculum vitae and a letter of intent addressed to Dr. Alena Gros via email to selecciorrhh@vhio.net, including the reference “Ref. 2024-026-01” in the subject line of your email.
Review of applications will commence immediately.
About VHIO:
Under the leadership of Josep Tabernero, the Vall d’Hebron Institute of Oncology (VHIO), has established itself as a comprehensive cancer center of proven excellence internationally. It is also thanks to VHIO’s optimal organizational structure based on a purely multidisciplinary and translational model that VHIO talents continue to anticipate and tackle the many unresolved questions in combatting this multifaceted and heterogeneous disease.
Located within the Vall d’Hebron Barcelona Hospital Campus, our researchers closely collaborate and interact with Vall d’Hebron physician-scientists. Translational science and clinical research are therefore tightly connected which promotes superb interaction and teamwork which, in turn, accelerates the bench-bedside-bed cycle of knowledge. This privileged environment affords VHIO direct access to patients as well as the entire spectrum of oncology professionals who care for them, and a second-to-none appreciation of how cancer science can translate into more powerful, targeted treatments and better practice for the care of patients.
VHIO’s pioneering model and programs, coupled with its belief in combining strengths through cross-border collaborations, continue to spur advances in reversing cancer resistance, halting metastatic spread, and more effectively treating even the most undruggable tumor types.
VHIO’s translation toward precision oncology: http://www.vhio.net